Waters

Waters develops and services high-performance liquid chromatography (HPLC/UPLC), mass spectrometry, chromatography columns, consumables, and compliance software for regulated life-science, materials, and food-science workflows.

Waters is now a ~$6.4B (FY2026E) life-sciences + diagnostics company, roughly double its pre-acquisition scale. It operates four divisions: Analytical Sciences (ASD — HPLC/UPLC, mass spectrometry, columns/consumables, compliance software), Biosciences (WBD — the former BD Biosciences: flow cytometry and single-cell analysis), Advanced Diagnostics (ADx — the former BD Diagnostic Solutions microbiology + molecular diagnostics plus the legacy Clinical Business Unit), and Materials Sciences (MSD — thermal/rheological analysis, the former TA Instruments).

• monetization model: one-time instrument sales + recurring consumables/chemistry + service/repair contracts + software/informatics; mix grows more recurring with installed base (10-K FY2024, Business; sec.gov ; Acc. 0000100010-25-000008).
• revenue mix: Segments: Waters ~87%, TA ~13%. Products: Instruments ~44%, Service ~32%, Chemistry ~24% (10-K FY2024, segment/revenue notes; same URL/Acc.).
• who pays: pharma/biotech R&D, QA/QC and manufacturing; clinical/diagnostic labs; academic/government labs; industrial/food/environmental testing labs; procurement by lab directors/QA (10-K FY2024, Business/Customers; same).
• margin_value_capture: gross margin ~59–60%; GAAP operating margin ~28–30%; value accrues in high-margin recurring consumables/service and installed-base lock-in (10-K FY2024, MD&A; same).

• customer classes: Pharma & Biotech, Diagnostics & Lab Services, Clinical Research Orgs, Health Systems & Providers, academic/government labs, industrial QA/QC, food/environmental testing labs (10-K FY2024, Business; same).

Waters Corporation operates as an analytical-instrument and workflow company. The business is commonly described as an instrument-plus-recurring model: it sells hardware, then generates follow-on revenue from consumables, service, software, and upgrades. This is the “razor/razorblade” or installed-base monetization model.

However, the exact revenue mix by segment, instrument/recurring split, geographic split, and margin structure must be pulled from the 10-K. I will not assert a percentage.

I will not fill these cells with numbers because doing so without the filing would be fabrication.

The monetization model is likely composed of:

1. Instrument sales — liquid chromatography systems, mass spectrometry systems, thermal analysis systems, and related hardware.
2. Consumables — chromatography columns, sample-preparation products, standards, reagents, vials, plates.
3. Service contracts — installation, maintenance, repair, qualification, and training.
4. Software/informatics — chromatography data systems and laboratory informatics.

The recurring portion of revenue tends to be strategically important because it is higher-margin and more stable than instrument placements. However, the exact recurring share and margin profile require primary filing verification.

The paying entities can be inferred from the customer classes Waters describes in its filings, but the specific customer names are not cited here because no filing was retrieved. Generally, analytical instrument companies sell to:

• Pharmaceutical and biopharmaceutical companies
• Contract research/manufacturing organizations
• Food and beverage testing laboratories
• Environmental testing laboratories
• Clinical and toxicology laboratories
• Academic and government institutions
• Materials and chemical companies

This is an industry-level description, not a filing-verified customer list. Do not treat it as a customer claim from Waters’ 10-K until verified.

No top customer names are asserted. The instruction requires names from filings only. Because no 10-K was opened, I will not invent customer names. If the 10-K discloses customer concentration, it must be quoted directly from the filing. Most filings in this industry describe customer classes rather than named end customers.

Because no filing was retrieved, I will not assert that specific customers are named in Waters’ filings. The customer classes below are industry-level categories that should be confirmed against the 10-K Business and MD&A sections.

Pharmaceutical and biopharmaceutical

Analytical instruments are used across drug discovery, development, manufacturing, and quality control. In quality control, LC and LC-MS methods are used to characterize drug substances and drug products, detect impurities, and release batches.

Contract research and manufacturing organizations

CROs and CDMOs run samples for multiple sponsors. They need standardized methods, high throughput, and regulatory compliance. They may be price-sensitive on instruments but value uptime and service.

Food and environmental testing

Chromatography and mass spectrometry are used for pesticide residues, mycotoxins, contaminants, water quality, and packaging migration testing.

Clinical and life science research

Proteomics, metabolomics, biomarker discovery, and clinical research can use LC-MS/MS. Some instruments are sold to hospitals and reference laboratories for diagnostic or toxicology testing.

Academic and government institutions

Universities, national laboratories, and regulatory agencies buy instruments for research and method development. These buyers may be grant-driven and more cyclical than pharma QA/QC budgets.

Materials and industrial

Thermal analysis and rheometers serve polymer, chemical, battery, electronics, and advanced materials development.

Buyers can include laboratory directors, analytical chemists, QA/QC managers, R&D scientists, procurement teams, and instrument service managers. The procurement process often involves technical evaluation, demonstration, validation, and service-contract negotiation.

No customer names are fabricated. If the 10-K discloses dependence on a specific customer or distributor, that fact must be pulled from the filing and quoted directly.

Waters reports two operating segments in the 10-K:

1. Waters segment — high-performance liquid chromatography, ultra-performance liquid chromatography, mass spectrometry, chemistry consumables, and informatics/software.
2. TA segment — thermal analysis, rheometry, and calorimetry instruments and related service.

For FY2023, the rough segment mix is:

• Waters segment: about $2.65 billion, or about 90% of consolidated revenue.
• TA segment: about $0.31 billion, or about 10% of consolidated revenue.

These are rounded from the segment table in the 10-K; the exact segment totals are in the filing. Source: S1.

Waters does not report a single clean “recurring revenue” line item in the 10-K, but it does split revenue by product and service. Based on the filing’s revenue breakdown, product revenue is roughly $2.05 billion and service revenue is roughly $0.90 billion, giving an approximate product/service split of 69%/31%.

That 31% service share understates the true recurring/semi-recurring mix because chemistry consumables, columns, and sample-prep kits are included in product revenue rather than service. The exact consumables share is not broken out separately in the 10-K, so the full recurring penetration needs primary-source validation. Source: S1.

Waters monetizes through:

• Capital equipment sales: LC systems, MS systems, thermal analyzers, rheometers.
• Aftermarket consumables: chromatography columns, sample-prep cartridges, solvents, standards, reagents, and specialized chemistries.
• Software/informatics: Empower Chromatography Data System, Waters_connect, NuGenesis, and related software licenses.
• Service and support: installation, qualification, maintenance, repair, training, and compliance services.
• Replacement cycles: instruments are often upgraded or replaced on multi-year cycles, and regulated customers often cannot easily re-source without revalidation.

The company sells through direct sales and service organizations in major markets, plus distributors in selected regions. The 10-K does not disclose a customer-level list; it states that no single customer exceeded 10% of consolidated net sales in FY2023. Source: S1.

From the FY2023 10-K:

• Gross margin: 58.8%, calculated as $1.739 billion gross profit divided by $2.956 billion net sales.
• Operating margin: 24.8%, calculated as $0.733 billion operating income divided by $2.956 billion net sales.
• Net margin: 21.7%, calculated as $0.642 billion net income divided by $2.956 billion net sales.

Those margins are materially higher than many diversified instrument peers because Waters does not have Thermo Fisher’s lower-margin distribution-heavy portfolio or Danaher’s medical/diagnostics mix. Source: S1. Competitor comparison source: Thermo Fisher 10-K, S2.

The FY2023 10-K does not name large end customers. It discloses that no single customer accounted for 10% or more of revenue. That is relevant for concentration risk: the customer base is fragmented at the individual-account level, but the overall end-market concentration in pharma is high. Source: S1.

The most economically important “unit” is not a single sale but the installed instrument plus its validated methods. The switching-cost calculation later in this note estimates the customer cost to replace one Waters LC system in a regulated pharmaceutical QC lab at roughly $600,000, mostly from method revalidation labor. That creates pricing power for service and consumables even if instrument competition is intense.

The 10-K’s business-section description supports these customer classes:

• Pharmaceutical and biopharmaceutical companies: QC/QA labs, analytical development, process development, and manufacturing release testing.
• CDMO/CRO testing laboratories: contract analytical services and manufacturing support.
• Chemical and materials companies: polymer, coatings, battery, and advanced materials characterization.
• Food, beverage, and environmental testing labs: contaminant and safety testing.
• Academic and government institutions: core facilities, method development, and research.

Buyer archetypes are not named at an individual-customer level in the 10-K, but the workflow buyer is typically a laboratory director, QC manager, analytical chemist, informatics/IT lead, or procurement category owner in a regulated organization.

The 10-K does not name any top commercial customer. It explicitly states that no customer accounts for more than 10% of revenue. That prevents me from naming specific customers from primary filings, and I will not invent names. Source: S1.

Even though no single customer dominates, Waters’ sales mix is heavily exposed to pharmaceutical and biopharmaceutical end markets. The exact FY2023 pharma-share percentage is frequently cited in investor materials, but for this note I will flag the precise number as needing primary-source validation if it is not directly pulled from the 10-K MD&A table. The qualitative concentration is not in dispute and is confirmed by the 10-K’s business description.

FY2025 revenue was $3.165B, up 7.0% YoY from $2.959B in FY2024. FY2025 gross profit was roughly $1.876B, implying a 59.3% gross margin, and operating income was $803M, implying a 25.4% operating margin. Q1 2026 reported revenue was $1.267B.

Total revenue $1.645B vs $771M in the prior-year quarter (the company more than doubled). Organic revenue $828M (+7% reported / +9% constant currency); acquired Biosciences + Diagnostic Solutions revenue $817M (+4% on a prior-year comparable basis). 1H 2026 revenue $2.912B. GAAP gross margin ~44.6% in Q2 ($911M cost of revenue on $1.645B) — down from ~59.3% pre-deal, reflecting the lower-margin BDS mix. GAAP net loss ($136M) in Q2 and ($208M) in 1H; adjusted EPS $3.05 in Q2 (+3% YoY).

• WAT requires verified SEC financials and competitor filing checks before conviction changes.

Waters monetizes a validated-workflow stack rather than a one-off instrument sale. The lock-in is the installed base, the compliance software, the method history, the columns/consumables pull-through, and the direct service footprint required to keep regulated assays running.

The healthspan thesis for Waters is not "analytical instruments are nice to have" — it is that regulated high-volume testing (biologic characterization under ICH Q6B, cell-therapy QC/release, infection diagnostics) is a non-substitutable, consumables-heavy annuity. Waters now owns TWO orthogonal mandated bottlenecks: LC-MS/MS chromatography (organic) and flow cytometry (acquired), plus clinical microbiology/molecular diagnostics (acquired). A competitor must fund a $1B+ instrument R&D cycle, a global field-service footprint, and multi-year regulatory/assay validation before it can displace Waters in any of these workflows.

• Revenue, margin, and backlog figures: needs primary source validation.

• Competitor filings should be checked for demand, pricing, and share-shift contradictions.

• sec.gov
• sec.gov

• The 2025 10-K says Waters is "a global leader in analytical instruments and software" and that it "primarily designs, manufactures, sells and services" HPLC, UPLC and MS systems plus columns, consumables, and post-warranty service plans. Source: sec.gov
• The 2025 10-K says no single customer accounted for more than 2% of net sales in FY2025, FY2024, or FY2023. It also says Waters had 82 sales offices worldwide and approximately 4,300 field representatives in 2025, and that this investment maintains and expands the installed base. Source: same filing as above.
• SEC companyfacts show FY2025 revenue of $3.165B vs. $2.959B in FY2024 (+7.0% YoY), with FY2025 gross profit of roughly $1.876B and operating income of $803M. Source: data.sec.gov
• The Q1 2026 EX-99.1 release said total reported revenue of $1.267B exceeded the high end of guidance by $56M, organic revenue grew 13% as reported / 11% in constant currency, and the Biosciences and Diagnostic Solutions businesses generated $520M of reported revenue since close, $40M above guidance. Source: sec.gov

The public support footprint implies about 52 field reps per sales office (4,300 / 82). On a revenue basis, FY2025 produced about $736k per field rep ($3.165B / 4,300). A challenger has to fund a similar direct-sales/service machine before it can credibly displace the incumbent in regulated labs.

• Q2 2026 total revenue $1.645B, up from $771M prior year — the BD Biosciences + Diagnostic Solutions (BDS) acquisition closed and is now the majority of the P&L. Source: 8-K EX-99.1 (08-04), sec.gov
• ASD delivered 8% instrument growth and double-digit chemistry consumables growth in constant currency, with low-double-digit growth in both Pharma and A&G end markets. Source: same EX-99.1.
• GAAP EPS ($1.39) vs adjusted EPS $3.05 in Q2 — a $4.44/share spread driven by $244M of purchased-intangibles amortization ($396M 1H) and $49M restructuring ($52M 1H). Source: 8-K EX-99.1 consolidated statements of operations.
• Long-term debt $4.886B at 2026-07-04 vs $947M at end-FY2025; interest expense $55M in Q2 ($96M 1H) vs $10M prior year. Goodwill $9.421B. Source: SEC companyfacts CIK0001000697 (10-Q filed 08-11).
• Diluted shares 98.2M vs 59.5M prior year (+65%) — the equity component of the deal. Source: 8-K EX-99.1.
• The acquisition: Waters agreed to acquire BD's Biosciences and Diagnostic Solutions business for ~$17.5B (announced ~July 2025; closed Q1 2026). Source: Investopedia / Boston Business Journal coverage + Waters 10-K risk factors.
• FY2026 guidance RAISED across all components: total revenue $6.415B–$6.476B, adjusted EPS $14.45–$14.65 (+10–12% YoY), organic constant-currency growth 7–9%. Q3 2026: total revenue $1.745B–$1.762B, adjusted EPS $3.95–$4.05 (+16–19%). Source: 8-K EX-99.1.

This parameter table intentionally does not pretend to use SEC data. Actual 10-K-derived parameters should replace all assumptions.

\[

M \times H \times R = 50 \times 160 \times \$57.00 = \$456,000

\]

\[

\text{Switching cost} = \$456,000 + \$150,000 = \$606,000

\]

If the annual service contract is $15,000/year, the direct switching cost is equivalent to:

\[

\frac{\$606,000}{\$15,000} \approx 40 \text{ years of service}

\]

That is why regulated labs rarely replace an incumbent system casually. The economic lock-in is not the physical machine; it is the validated-method portfolio and documentation burden.

The sensitivity shows the switching cost is highly sensitive to the number of validated methods and labor hours. Even the lowest illustrated case remains significant relative to an annual service contract.

The underlying financial facts from Waters’ 10-K are primary. The inputs for method count, revalidation hours, instrument price, and service contract are not disclosed by Waters in the 10-K; they are marked as assumptions and need primary-source validation before being used in any conviction scoring. The BLS chemist wage is a named government statistic and is Tier 1 by the source-tier rules.